Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Stericycle

DB:SY9
Snowflake Description

Fair value with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SY9
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Commercial Services
Company description

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States, Europe, and internationally. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Stericycle has significant price volatility in the past 3 months.
SY9 Share Price and Events
7 Day Returns
-5.9%
DB:SY9
-1.9%
DE Commercial Services
-0.6%
DE Market
1 Year Returns
-19.2%
DB:SY9
-32.9%
DE Commercial Services
-20.9%
DE Market
SY9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Stericycle (SY9) -5.9% -23.3% -27% -19.2% -47.3% -69.3%
DE Commercial Services -1.9% -21.9% -35.2% -32.9% -36.8% -47.8%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • SY9 outperformed the Commercial Services industry which returned -32.9% over the past year.
  • SY9 outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
SY9
Industry
5yr Volatility vs Market

Value

 Is Stericycle undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Stericycle to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Stericycle.

DB:SY9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 4.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:SY9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Commercial Services Unlevered Beta Simply Wall St/ S&P Global 0.59
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.588 (1 + (1- 21%) (77.91%))
0.966
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.97
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.966 * 5.44%)
4.86%

Discounted Cash Flow Calculation for DB:SY9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Stericycle is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:SY9 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 4.86%)
2020 139.65 Analyst x4 133.17
2021 228.60 Analyst x4 207.88
2022 313.30 Analyst x2 271.69
2023 332.00 Analyst x1 274.55
2024 410.00 Analyst x1 323.32
2025 459.85 Est @ 12.16% 345.81
2026 498.44 Est @ 8.39% 357.45
2027 527.15 Est @ 5.76% 360.49
2028 547.78 Est @ 3.91% 357.22
2029 562.15 Est @ 2.62% 349.59
Present value of next 10 years cash flows $2,981.00
DB:SY9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $562.15 × (1 + -0.39%) ÷ (4.86% – -0.39%)
$10,656.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,656.22 ÷ (1 + 4.86%)10
$6,626.89
DB:SY9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,981.00 + $6,626.89
$9,607.89
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $9,607.89 / 91.27
$105.27
DB:SY9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:SY9 represents 0.93084x of NasdaqGS:SRCL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.93084x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 105.27 x 0.93084
€97.99
Value per share (EUR) From above. €97.99
Current discount Discount to share price of €40.78
= -1 x (€40.78 - €97.99) / €97.99
58.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Stericycle is available for.
Intrinsic value
>50%
Share price is €40.78 vs Future cash flow value of €97.99
Current Discount Checks
For Stericycle to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Stericycle's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Stericycle's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Stericycle's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Stericycle's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SY9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.81
NasdaqGS:SRCL Share Price ** NasdaqGS (2020-04-06) in USD $43.81
Germany Commercial Services Industry PE Ratio Median Figure of 6 Publicly-Listed Commercial Services Companies 94.45x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Stericycle.

DB:SY9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SRCL Share Price ÷ EPS (both in USD)

= 43.81 ÷ -3.81

-11.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stericycle is loss making, we can't compare its value to the DE Commercial Services industry average.
  • Stericycle is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Stericycle's expected growth come at a high price?
Raw Data
DB:SY9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
138%per year
Europe Commercial Services Industry PEG Ratio Median Figure of 48 Publicly-Listed Commercial Services Companies 1.09x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Stericycle, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Stericycle's assets?
Raw Data
DB:SY9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $25.56
NasdaqGS:SRCL Share Price * NasdaqGS (2020-04-06) in USD $43.81
Germany Commercial Services Industry PB Ratio Median Figure of 9 Publicly-Listed Commercial Services Companies 2.23x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:SY9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SRCL Share Price ÷ Book Value per Share (both in USD)

= 43.81 ÷ 25.56

1.71x

* Primary Listing of Stericycle.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Stericycle is good value based on assets compared to the DE Commercial Services industry average.
X
Value checks
We assess Stericycle's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. Stericycle has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Stericycle expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
138%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Stericycle expected to grow at an attractive rate?
  • Stericycle's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Stericycle's earnings growth is expected to exceed the Germany market average.
  • Stericycle's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:SY9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:SY9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 138%
DB:SY9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 1.5%
Germany Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 21%
Germany Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 2.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SY9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SY9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 3,644 1
2023-12-31 3,503 1
2022-12-31 3,437 3
2021-12-31 3,339 413 132 9
2020-12-31 3,243 347 71 10
2020-04-07
DB:SY9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 3,309 248 -347
2019-09-30 3,362 277 -446
2019-06-30 3,384 6 -369
2019-03-31 3,421 92 -312
2018-12-31 3,486 166 -253
2018-09-30 3,521 207 148
2018-06-30 3,549 501 166
2018-03-31 3,583 451 -9
2017-12-31 3,581 509 23
2017-09-30 3,599 535 -47
2017-06-30 3,607 554 -21
2017-03-31 3,581 572 165

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Stericycle's earnings are expected to grow significantly at over 20% yearly.
  • Stericycle's revenue is expected to grow by 1.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SY9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Stericycle Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SY9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 2.70 2.70 2.70 1.00
2021-12-31 1.53 2.04 0.91 6.00
2020-12-31 0.90 1.51 0.21 7.00
2020-04-07
DB:SY9 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.81
2019-09-30 -4.90
2019-06-30 -4.11
2019-03-31 -3.53
2018-12-31 -2.91
2018-09-30 1.73
2018-06-30 1.95
2018-03-31 -0.11
2017-12-31 0.27
2017-09-30 -0.55
2017-06-30 -0.25
2017-03-31 1.94

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Stericycle will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Stericycle's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Stericycle has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Stericycle performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Stericycle's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Stericycle does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Stericycle's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Stericycle's 1-year growth to the Europe Commercial Services industry average as it is not currently profitable.
Earnings and Revenue History
Stericycle's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Stericycle Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SY9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3,308.90 -346.80 768.50
2019-09-30 3,361.70 -445.90 739.00
2019-06-30 3,383.50 -369.20 802.40
2019-03-31 3,421.00 -312.10 810.70
2018-12-31 3,485.90 -253.30 804.90
2018-09-30 3,521.00 148.40 814.50
2018-06-30 3,548.90 166.40 811.60
2018-03-31 3,583.30 -9.00 814.20
2017-12-31 3,580.70 23.40 840.20
2017-09-30 3,599.25 -47.21 986.95
2017-06-30 3,606.60 -21.17 1,025.41
2017-03-31 3,580.52 164.92 965.33
2016-12-31 3,562.30 178.20 777.10
2016-09-30 3,544.25 236.23 715.11
2016-06-30 3,372.70 244.14 660.87
2016-03-31 3,196.77 294.68 604.69
2015-12-31 2,985.90 256.90 594.30
2015-09-30 2,774.55 268.75 506.29
2015-06-30 2,723.83 282.14 495.10
2015-03-31 2,648.97 276.25 481.99
2014-12-31 2,555.60 326.46 433.87
2014-09-30 2,446.55 322.09 427.91
2014-06-30 2,313.26 319.80 407.54
2014-03-31 2,198.96 315.90 384.03
2013-12-31 2,142.81 311.37 380.31
2013-09-30 2,078.55 303.28 358.86
2013-06-30 2,024.45 288.21 352.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Stericycle has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Stericycle has efficiently used its assets last year compared to the DE Commercial Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Stericycle improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Stericycle's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Stericycle has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Stericycle's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Stericycle's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Stericycle's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Stericycle's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Stericycle's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Stericycle Company Filings, last reported 3 months ago.

DB:SY9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 2,334.70 2,633.90 34.70
2019-09-30 2,477.30 2,714.10 30.80
2019-06-30 2,562.20 2,798.20 34.50
2019-03-31 2,570.50 2,793.00 48.20
2018-12-31 2,597.10 2,762.70 34.30
2018-09-30 2,932.60 2,838.00 52.00
2018-06-30 2,901.60 2,654.50 45.00
2018-03-31 2,952.10 2,720.70 49.40
2017-12-31 2,908.60 2,741.80 42.20
2017-09-30 2,818.72 2,778.50 52.17
2017-06-30 2,760.82 2,861.22 44.19
2017-03-31 2,892.48 2,863.34 47.02
2016-12-31 2,816.40 2,954.50 44.20
2016-09-30 2,858.79 3,012.78 40.35
2016-06-30 2,829.08 3,118.46 44.38
2016-03-31 2,818.49 3,152.15 45.72
2015-12-31 2,747.84 3,201.76 55.70
2015-09-30 2,734.44 1,516.09 669.17
2015-06-30 1,982.02 1,668.01 33.06
2015-03-31 1,950.01 1,575.39 38.40
2014-12-31 1,917.19 1,659.22 22.62
2014-09-30 1,880.19 1,677.41 42.46
2014-06-30 1,852.34 1,715.20 25.81
2014-03-31 1,785.55 1,370.38 43.41
2013-12-31 1,767.54 1,431.04 67.58
2013-09-30 1,722.73 1,403.17 64.03
2013-06-30 1,649.44 1,318.63 18.46
  • Stericycle's level of debt (112.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (86.5% vs 112.8% today).
  • Debt is not well covered by operating cash flow (9.4%, less than 20% of total debt).
  • Stericycle is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess Stericycle's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Stericycle has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Stericycle's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Stericycle dividends. Estimated to be 0% next year.
If you bought €2,000 of Stericycle shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Stericycle's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Stericycle's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SY9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Germany Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 5.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SY9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-07

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Stericycle has not reported any payouts.
  • Unable to verify if Stericycle's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Stericycle's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Stericycle has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Stericycle's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Stericycle's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Stericycle afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Stericycle has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Stericycle's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cindy Miller
COMPENSATION $2,375,730
AGE 56
TENURE AS CEO 0.9 years
CEO Bio

Ms. Cindy J. Miller has been the President of Stericycle, Inc. since October 1, 2018, Chief Executive Officer since May 2, 2019 and as its Director since February 28, 2019. Ms. Miller served as Chief Operating Officer of Stericycle, Inc. from October 1, 2018 to May 2, 2019. Ms. Miller is responsible for the global operations of the Stericycle's medical waste, hazardous waste and secure information destruction lines, as well as the execution of Stericycle's Business Transformation. Ms. Miller joined Stericycle in October 2018 as part of an executive leadership development and succession planning process. Previously, Ms. Miller had a successful 30-year career at United Parcel Service (UPS) where she served in multiple roles of increasing leadership and international responsibility. She served as President of Global Freight Forwarding for United Parcel Service (UPS). She was President of UPS Europe SPRL/BVBA from April 3, 2013 to February 2, 2016. Ms. Miller holds a B.A. in Humanities and Business from Pennsylvania State University and an Executive MBA from the London Business School.

CEO Compensation
  • Insufficient data for Cindy to compare compensation growth.
  • Cindy's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Stericycle management team in years:

1.3
Average Tenure
56
Average Age
  • The average tenure for the Stericycle management team is less than 2 years, this suggests a new team.
Management Team

Cindy Miller

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
0.9 yrs

Kurt Rogers

TITLE
Executive VP
COMPENSATION
$1M
AGE
47
TENURE
2.8 yrs

Dan Ginnetti

TITLE
Executive Vice President of International
COMPENSATION
$2M
AGE
50
TENURE
0.8 yrs

Janet Zelenka

TITLE
Executive VP & CFO
AGE
60
TENURE
0.8 yrs

Rich Hoffman

TITLE
Senior VP & Chief Accounting Officer
AGE
52
TENURE
2.9 yrs

David Stahl

TITLE
Executive VP & Chief Information Officer
AGE
54
TENURE
2 yrs

Jennifer Koenig

TITLE
Vice President of Corporate Communications & Investor Relations

Michael Weisman

TITLE
Executive VP and Chief Ethics & Compliance Officer
AGE
60
TENURE
2 yrs

Joe Reuter

TITLE
Executive VP & Chief People Officer
AGE
57
TENURE
1.3 yrs

Rich Moore

TITLE
Executive Vice President of North American Operations
AGE
57
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Stericycle board of directors in years:

2
Average Tenure
64
Average Age
  • The average tenure for the Stericycle board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bob Murley

TITLE
Chairman
COMPENSATION
$260K
AGE
69
TENURE
2.1 yrs

Cindy Miller

TITLE
President
COMPENSATION
$2M
AGE
56
TENURE
1.2 yrs

Mike Zafirovski

TITLE
Independent Director
COMPENSATION
$185K
AGE
65
TENURE
7.4 yrs

Lynn Bleil

TITLE
Independent Director
COMPENSATION
$191K
AGE
56
TENURE
4.9 yrs

Brian Anderson

TITLE
Independent Director
COMPENSATION
$200K
AGE
68
TENURE
3.3 yrs

Thomas Chen

TITLE
Independent Director
COMPENSATION
$185K
AGE
69
TENURE
5.9 yrs

Kay Priestly

TITLE
Independent Director
COMPENSATION
$149K
AGE
63
TENURE
1.8 yrs

Ronee Hagen

TITLE
Independent Director
COMPENSATION
$149K
AGE
73
TENURE
1.8 yrs

J. Hackney

TITLE
Independent Director
AGE
49
TENURE
1.1 yrs

Steve Hooley

TITLE
Independent Director
AGE
55
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Stericycle's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Stericycle has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Stericycle, Inc., together with its subsidiaries, provides regulated and compliance solutions to the healthcare, retail, and commercial businesses in the United States, Europe, and internationally. It operates through three segments: North America RWCS; International RWCS; and Domestic Communication and Related Services. It collects and processes regulated and specialized waste for disposal services; and collects personal and confidential information for secure destruction, recall/return, and communication services. The company’s services also include medical waste disposal, pharmaceutical waste disposal, hazardous waste management, sustainability solutions for expired or unused inventory, secure information destruction of documents and e-media, and compliance services; and regulated recall and returns management communication, logistics, and data management services for expired, withdrawn, or recalled products. In addition, it offers compliance programs under the Steri-Safe, Clinical Services, First Practice Management, SeguriMed, and EnviroAssure brand names. The company serves healthcare businesses, including hospitals, physician and dental practices, outpatient clinics, long-term care facilities, etc.; retailers and manufacturers; financial and professional service providers; governmental entities; and other businesses. Stericycle, Inc. was founded in 1989 and is headquartered in Bannockburn, Illinois.

Details
Name: Stericycle, Inc.
SY9
Exchange: DB
Founded: 1989
$3,706,293,600
91,271,184
Website: http://www.stericycle.com
Address: Stericycle, Inc.
2355 Waukegan Road,
Bannockburn,
Illinois, 60015,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SRCL Common Stock Nasdaq Global Select US USD 23. Aug 1996
DB SY9 Common Stock Deutsche Boerse AG DE EUR 23. Aug 1996
LSE 0L9O Common Stock London Stock Exchange GB USD 23. Aug 1996
ETLX SY9 Common Stock Eurotlx IT EUR 23. Aug 1996
Number of employees
Current staff
Staff numbers
19,500
Stericycle employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 00:01
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/28
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.